Abzena Capabilities Update June 2026: ADC

Antibody-Oligonucleotide Conjugates (AOCs) represent a powerful leap forward in targeted gene modulation, expanding therapeutic delivery far beyond the liver into complex tissues like the central nervous system and tumors. However, realizing their full potential requires overcoming intricate molecular hurdles. Precise control over the oligo-antibody ratio is paramount, as higher loading ratios drastically accelerate plasma clearance and fuel product aggregation. Furthermore, managing the unique thermodynamic behavior of oligonucleotide strands demands specialized pre-annealing workflows to prevent severe precipitation during conjugation. Navigating these biophysical challenges requires robust analytical frameworks, incorporating advanced ion-exchange chromatography and orthogonal matrix testing to secure exceptional purity and stability.

Discover how integrated development platforms and innovative linkers successfully de-risk the scale-up process from benchtop discovery to full-scale clinical manufacturing—access the complete presentation today to optimize your bioconjugation pipeline.